The goal of the study is to look at the relationship between how individuals with Sarcoidosis take the sarcoidosis medicines and how it affects the disease, to evaluate any factors that may make individuals not want to take the medicines, and to develop and refine ways to help support individuals with Sarcoidosis especially when it comes to the medicines. The overall hypothesis is higher medication adherence will be associated with better clinical outcomes in sarcoidosis. The investigators will enroll 150 patients with biopsy proven pulmonary sarcoidosis for at least one year who are on any oral treatment regimen for at least six months into a 12-month longitudinal study.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Change in King's Sarcoidosis Health Questionnaire (KSQ) score
Timeframe: Baseline, 6 months and 12 months
Change in St. George's Respiratory Questionnaire (SGRQ) score
Timeframe: Baseline, 6 months and 12 months
Change in Forced Expiratory Volume (FEV1) as assessed by Pulmonary Function Testing
Timeframe: Baseline, 6 months and 12 months
Change in Forced Vital Capacity (FVC) as assessed by Pulmonary Function Testing
Timeframe: Baseline, 6 months and 12 months
Change in Diffusing Capacity of Lung for Carbon Monoxide (DLCO) as assessed by Pulmonary Function Testing
Timeframe: Baseline, 6 months and 12 months
Change in 6-minute walk distance
Timeframe: Baseline, 6 months and 12 months
Change in Modified Medical Research Council Dyspnea Scale (MRC) score
Timeframe: Baseline, 6 months and 12 months
Change in Health Care Utilization (HCU) as assessed by the CRISP Database
Timeframe: 12 months prior to enrollment and the duration of the study for a total of 24 months